GEM103

GEM103 · Gemini Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GEM103, covering 2022-10-31 to 2022-10-31. Get the full timeline:

Most recent: Clinical Trial Update: A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration [Phase 2]

See pricing